Immunic Stock Z Score

IMUX Stock  USD 1.30  0.02  1.56%   
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Immunic Piotroski F Score and Immunic Valuation analysis.
For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.
  
At this time, Immunic's Change In Working Capital is fairly stable compared to the past year. Capital Expenditures is likely to rise to about 496.2 K in 2024, whereas Capital Surpluse is likely to drop slightly above 326.3 M in 2024. At this time, Immunic's Research Development is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 5.9 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 105.5 K in 2024.

Immunic Z Score Analysis

Immunic's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
 2021 2022 2023 2024 (projected)
Short and Long Term Debt Total584K1.6M1.3M955.9K
Total Assets139.1M127.8M54.3M81.3M

Z Score

 = 

Sum Of

5 Factors

More About Z Score | All Equity Analysis

Current Immunic Z Score

    
  36.58  
Most of Immunic's fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunic is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

First Factor

 = 

1.2 * (

Working Capital

/

Total Assets )

Second Factor

 = 

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

 = 

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

 = 

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

 = 

0.99 * (

Revenue

/

Total Assets )

Immunic Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Immunic is extremely important. It helps to project a fair market value of Immunic Stock properly, considering its historical fundamentals such as Z Score. Since Immunic's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immunic's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immunic's interrelated accounts and indicators.
0.210.96-0.95-0.040.570.550.33-0.530.97-0.23-0.480.280.340.15-0.410.420.720.440.780.74-0.410.28
0.210.12-0.27-0.60.410.060.4-0.070.31-0.18-0.380.60.280.63-0.37-0.150.130.24-0.25-0.170.270.65
0.960.12-0.94-0.040.550.510.38-0.730.93-0.14-0.60.320.180.13-0.380.370.590.420.710.66-0.40.15
-0.95-0.27-0.940.03-0.68-0.41-0.340.56-0.980.340.49-0.36-0.36-0.240.25-0.42-0.61-0.28-0.68-0.70.2-0.17
-0.04-0.6-0.040.030.13-0.24-0.880.19-0.09-0.150.3-0.840.12-0.790.520.35-0.22-0.470.190.13-0.27-0.64
0.570.410.55-0.680.130.19-0.03-0.330.65-0.33-0.410.240.30.140.070.030.19-0.010.120.150.070.19
0.550.060.51-0.41-0.240.190.4-0.220.51-0.06-0.20.320.230.35-0.38-0.270.750.510.490.44-0.120.69
0.330.40.38-0.34-0.88-0.030.4-0.420.380.04-0.390.860.00.78-0.52-0.110.40.540.180.220.160.51
-0.53-0.07-0.730.560.19-0.33-0.22-0.42-0.52-0.160.79-0.380.36-0.060.25-0.03-0.07-0.27-0.17-0.10.250.07
0.970.310.93-0.98-0.090.650.510.38-0.52-0.35-0.450.380.40.28-0.320.370.710.340.70.73-0.210.3
-0.23-0.18-0.140.34-0.15-0.33-0.060.04-0.16-0.35-0.170.06-0.68-0.18-0.55-0.25-0.190.57-0.25-0.42-0.47-0.02
-0.48-0.38-0.60.490.3-0.41-0.2-0.390.79-0.45-0.17-0.450.3-0.120.34-0.020.06-0.320.00.120.27-0.11
0.280.60.32-0.36-0.840.240.320.86-0.380.380.06-0.45-0.080.87-0.45-0.290.250.45-0.070.010.340.55
0.340.280.18-0.360.120.30.230.00.360.4-0.680.3-0.080.320.070.420.50.010.450.570.250.32
0.150.630.13-0.24-0.790.140.350.78-0.060.28-0.18-0.120.870.32-0.34-0.230.360.38-0.030.120.590.67
-0.41-0.37-0.380.250.520.07-0.38-0.520.25-0.32-0.550.34-0.450.07-0.34-0.05-0.49-0.93-0.29-0.180.5-0.54
0.42-0.150.37-0.420.350.03-0.27-0.11-0.030.37-0.25-0.02-0.290.42-0.23-0.050.160.040.610.58-0.35-0.43
0.720.130.59-0.61-0.220.190.750.4-0.070.71-0.190.060.250.50.36-0.490.160.530.760.8-0.190.6
0.440.240.42-0.28-0.47-0.010.510.54-0.270.340.57-0.320.450.010.38-0.930.040.530.350.22-0.440.55
0.78-0.250.71-0.680.190.120.490.18-0.170.7-0.250.0-0.070.45-0.03-0.290.610.760.350.96-0.470.05
0.74-0.170.66-0.70.130.150.440.22-0.10.73-0.420.120.010.570.12-0.180.580.80.220.96-0.220.08
-0.410.27-0.40.2-0.270.07-0.120.160.25-0.21-0.470.270.340.250.590.5-0.35-0.19-0.44-0.47-0.220.15
0.280.650.15-0.17-0.640.190.690.510.070.3-0.02-0.110.550.320.67-0.54-0.430.60.550.050.080.15
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition

According to the company's disclosures, Immunic has a Z Score of 36.58. This is much higher than that of the Biotechnology sector and notably higher than that of the Health Care industry. The z score for all United States stocks is notably lower than that of the firm.

Immunic Z Score Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunic's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunic could also be used in its relative valuation, which is a method of valuing Immunic by comparing valuation metrics of similar companies.
Immunic is currently under evaluation in z score category among related companies.

Immunic Institutional Holders

Institutional Holdings refers to the ownership stake in Immunic that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Immunic's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Immunic's value.
Shares
Sierra Summit Advisors Llc2023-12-31
324.8 K
Cowen And Company, Llc2023-12-31
317.1 K
Soleus Capital Management, L.p.2023-12-31
300 K
Innovis Asset Management Llc2023-09-30
272.5 K
Schonfeld Strategic Advisors Llc2023-09-30
238.7 K
Northern Trust Corp2023-12-31
164.4 K
Two Sigma Advisers, Llc2023-12-31
147.4 K
State Street Corporation2023-12-31
125.8 K
Two Sigma Investments Llc2023-12-31
116.5 K
Rtw Investments, Llc2023-12-31
4.3 M
Gratus Capital Llc2023-12-31
1.9 M

Immunic Fundamentals

About Immunic Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Immunic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. t and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 65 people.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Immunic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunic Stock:
Check out Immunic Piotroski F Score and Immunic Valuation analysis.
For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Complementary Tools for Immunic Stock analysis

When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Fundamental Analysis
View fundamental data based on most recent published financial statements
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Is Immunic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.11)
Return On Assets
(0.68)
Return On Equity
(1.31)
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.